TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05074199

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: W-plasty/Linear closure
Description: The patient's wound will be labeled A if it is on the left or superior side of the investigator and B if it is on the right or inferior side. A predetermined, concealed randomization number will be obtained from the RedCap randomization module, which will specify how side A is to be treated. Side B will be treated the opposite way as A. Side A will always be closed first. The side assigned to be closed in a traditional straight line (SL) will have the standing cutaneous deformity (dog ear) excised in the standard manner using Burrow's triangles, resulting in an elliptical defect amenable to linear closure. The side assigned to be closed with W-plasty will have the dog ear excised in a zig-zag fashion consistent with the W plasty flap design. Both sides of the wound will receive subcuticular closure with interrupted subdermal sutures as is the standard of care, followed by a standard running cuticular closure with absorbable suture material.
Study: NCT04581902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS therapy
Description: rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS therapy
Description: rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.
Study: NCT05409196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ShigETEC live, attenuated, oral vaccine
Description: Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
Study: NCT01272713

Intervention type: OTHER
Group type: OTHER
Intervention: Oxygen therapy
Description: * Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~* In-hospital oxygen as per hospital protocol

Intervention type: OTHER
Group type: OTHER
Intervention: No oxygen therapy
Description: No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.
Study: NCT01476917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attune Sleep Apnea System
Description: Observation of Attune Sleep Apnea System for use during sleep.
Study: NCT03665883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar energy
Description: Monopolar energy in TEP for inguinal hernia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blunt dissection
Description: Blunt dissection in TEP for inguinal hernia
Study: NCT03752762

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SQ-LNS
Description: SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study will not include sugar.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPOON behavioral change strategy
Description: An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits and group sessions.
Study: NCT03423160

Intervention type: OTHER
Intervention: None--observational
Description: Observational study of behavior and electrical brain activity

Intervention type: OTHER
Intervention: None--observational
Description: Observational study of behavior and electrical brain activity
Study: NCT02637050

Intervention type: OTHER
Intervention: Standard of care
Description: At the discretion of the attending physician.
Study: NCT02329600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: green tea tablets (Green tea extract 5:1) 200 mg
Description: Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
Study: NCT00926575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral beclomethasone 17,21-dipropionate
Description: Two tablets QID for 50 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets QID for 50 days
Study: NCT00652483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine ophthalmic solution 0.1%
Description: 1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine ophthalmic solution 0.2%
Description: 1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
Study: NCT03297762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gamification
Description: incentives/rewards and contact between standard visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Dexcom G5
Description: Dexcom G5 continuous glucose monitor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use of Dexcom G5
Description: Dexcom G5 continuous glucose monitor
Study: NCT00962806

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 8 weeks of intensive exercise, 60-90 minutes 3 days each week

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle counseling
Description: Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
Study: NCT03855176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaqta Injectable Product
Description: Inactive vaccine against hepatitis A virus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaqta Injectable Product
Description: Inactive vaccine against hepatitis A virus
Study: NCT02565550

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low FODMAPs
Description: low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low FODMAPs
Description: low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols
Study: NCT01649557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: oral administered once daily
Study: NCT03356964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: follicle stimulating hormone
Description: Follicle stimulating hormone( will be chosen according to ovarian reserve parameters in the study group the dosage will be reduced in the control group it will remain unchanged

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: follicle stimulating hormone
Description: Follicle stimulating hormone( will be chosen according to ovarian reserve parameters in the study group the dosage will be reduced in the control group it will remain unchanged
Study: NCT00401401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zalutumumab
Description: Eight weekly infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zalutumumab
Description: Eight weekly infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zalutumumab
Description: Eight weekly infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zalutumumab
Description: Eight weekly infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Infusions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Daily in the treatment period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Daily in the treatment period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Daily in the treatment period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Daily in the treatment period
Study: NCT04611282

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical techniques in the treatment of localized gingival recession defects.
Description: Micro or macrosurgical echniques were performed using a coronally positioned flap with a subepithelial connective tissue graft.
Study: NCT03630406

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal Tactile Imaging
Description: Vaginal Tactile Imaging
Study: NCT04072445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study: NCT04611282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical techniques in the treatment of localized gingival recession defects.
Description: Micro or macrosurgical echniques were performed using a coronally positioned flap with a subepithelial connective tissue graft.
Study: NCT03634202

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IMRT + oral chemotherapy
Description: It's a dose escalation of radiation (IMRT), during 5 to 7 weeks, 5 days per week.~Concomitantly, patient have oral chemotherapy (capecitabin)
Study: NCT00632632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality with D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
Study: NCT02281500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Plasma-Derived Fibrinogen Concentrate
Description: A sterile freeze-dried fibrinogen concentrate filled in vials containing 1 g of FIB Grifols. FIB Grifols contains 20 mg/ml of active substance fibrinogen when reconstituted.
Study: NCT00691600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral trimethoprim/sulfamethoxazole
Description: 80 mg caps or 8 mg/ml suspension every 12 hours for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo caps or suspension every 12 hours for 10 days
Study: NCT02600078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMS Monitor App
Description: Participants will complete a novel coordination task performed on an android phone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMS Monitor App
Description: Participants will complete a novel coordination task performed on an android phone.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AMS Monitor App
Description: Participants will complete a novel coordination task performed on an android phone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lake Louise Score
Description: Participants will complete a questionnaire to assess acclimatization to hypoxia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lake Louise Score
Description: Participants will complete a questionnaire to assess acclimatization to hypoxia.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lake Louise Score
Description: Participants will complete a questionnaire to assess acclimatization to hypoxia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Error Scoring System
Description: Participants will complete a series of static stance positions to evaluate their ability to maintain balance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Error Scoring System
Description: Participants will complete a series of static stance positions to evaluate their ability to maintain balance.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Balance Error Scoring System
Description: Participants will complete a series of static stance positions to evaluate their ability to maintain balance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart Rate & Pulse Oxygen Saturation
Description: Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart Rate & Pulse Oxygen Saturation
Description: Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Heart Rate & Pulse Oxygen Saturation
Description: Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.
Study: NCT03866096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The player will perform exercises of balance, stability, and strengthening of the abdomen, back and gluteus. All these exercises will be carried out in first instance on flat surfaces and later on unstable surfaces to increase the difficulty of it. The training will be done in different levels of difficulty, once the participant managed to master the initial level, advance to the next level to complete the three levels of difficulty during the 6 weeks of training. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of the intervention of the experimental group will last 20 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Neuromuscular training will be applied through balance and stability exercises on both flat and unstable surfaces. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of each session of the control group is 10 minutes.
Study: NCT01261247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Optional correlative studies
Study: NCT03750253

Intervention type: OTHER
Group type: OTHER
Intervention: Extracorporeal Shock Wave Therapy
Description: Extracorporeal Shock Wave Therapy will be used for pain-relief after arthroscopy for osteochondral lesions of the talus
Study: NCT03070704

Intervention type: DRUG
Intervention: insulin degludec/liraglutide
Description: Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician
Study: NCT02214680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combigan (Combination of Brimonidine and Timolol)
Description: On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: 0.5% eye drop
Study: NCT02370901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helmet
Description: Custom fitting helmet, FDA approved, to allow reshaping of the infant skull

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home therapies
Description: parents will be instructed to do home neck stretching exercises, as well as repositioning techniques to keep baby off the flat spot. They will also be offered reassurance.
Study: NCT00151827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Medications are taken once daily before breakfast with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide oral tablets
Description: If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
Study: NCT00632632

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality. Placebo given on days when receiving exposure with virtual reality (approximately 10-12 times).
Study: NCT02864316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT03500926

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total hip replacement - standard femoral stem
Description: total hip replacement with standard femoral stem

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: total hip replacement - short femoral stem
Description: total hip replacement with short femoral stem
Study: NCT02599337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexavar
Description: Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar
Description: Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose.
Study: NCT03420222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules
Study: NCT00151827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide oral tablets
Description: If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
Study: NCT02520310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVJ-514
Description: Patients receiving AVJ-514 device
Study: NCT00521885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arixtra (Fondaparinox) 2.5 mg SC Daily
Description: Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovenox 40mg SC Daily
Description: Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
Study: NCT01301885

Intervention type: PROCEDURE
Intervention: Laparoscopy/laparotomy
Description: Surgical treatment of endometriosis (laparotomy/laparoscopy) or laparoscopic sterilisation. Sample collection in both groups.

Intervention type: PROCEDURE
Intervention: Laparoscopy/laparotomy
Description: Surgical treatment of endometriosis (laparotomy/laparoscopy) or laparoscopic sterilisation. Sample collection in both groups.